Mydecine Innovations Group (STU:0NF0) Long-Term Debt : €3.75 Mil (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Mydecine Innovations Group Long-Term Debt?

Mydecine Innovations Group's Long-Term Debt for the quarter that ended in Sep. 2023 was €3.75 Mil.

Mydecine Innovations Group's quarterly Long-Term Debt increased from Mar. 2023 (€3.37 Mil) to Jun. 2023 (€3.59 Mil) and increased from Jun. 2023 (€3.59 Mil) to Sep. 2023 (€3.75 Mil).

Mydecine Innovations Group's annual Long-Term Debt increased from Dec. 2020 (€0.00 Mil) to Dec. 2021 (€3.01 Mil) and increased from Dec. 2021 (€3.01 Mil) to Dec. 2022 (€3.26 Mil).

Mydecine Innovations Group Long-Term Debt Historical Data

The historical data trend for Mydecine Innovations Group's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mydecine Innovations Group Long-Term Debt Chart

Mydecine Innovations Group Annual Data

Trend

Dec13

Aug14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Long-Term Debt

Get a 7-Day Free Trial

3.01

3.26

Mydecine Innovations Group Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Long-Term Debt	Get a 7-Day Free Trial															3.80	3.26	3.37	3.59	3.75

Mydecine Innovations Group (STU:0NF0) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Mydecine Innovations Group Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Mydecine Innovations Group's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Mydecine Innovations Group (STU:0NF0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mydecine Innovations Group Inc (STU:0NF0) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

MYCOF:USA MYIG:UK MYCO:Canada

Address

789 West Pender Street, Suite 810, Vancouver, BC, CAN, V6C 1H2

Website

https://www.mydecine.com

Mydecine Innovations Group Inc is a biopharma and life sciences company engaged in the research, drug development, and clinical trials of psilocybin products.

Mydecine Innovations Group (STU:0NF0) Headlines

No Headlines